• Company
• ‘The new ATTR-CM treatment can improve patient survival’
• by Whang, byung-woo Nov 27, 2024 05:50am

• Company
• Active development of new drugs for myasthenia gravis
• by Son, Hyung Min Nov 27, 2024 05:50am

• Company
• 4 of 5 listed pharma companies expand investments
• by Chon, Seung-Hyun Nov 26, 2024 05:54am

• Company
• Will Imfinzi and Imjudo be reimbursed in Korea?
• by Eo, Yun-Ho Nov 26, 2024 05:54am

• Company
• ‘Oral drugs can address the unmet PNH treatment needs’
• by Son, Hyung Min Nov 26, 2024 05:54am

• Company
• "Pharmaceutical companies using CSOs must renew contracts
• by Kim, Jin-Gu Nov 26, 2024 05:53am

• Company
• K-Bio to showcase at the ASH 2024
• by Son, Hyung Min Nov 25, 2024 05:54am

• Company
• 'Altuviiio' for hemophilia A expected to be marketed in KOR
• by Eo, Yun-Ho Nov 25, 2024 05:53am

• Company
• "Korean pharma draws attention, open innovation will heat up
• by Son, Hyung Min Nov 22, 2024 05:56am

• Company
• Industry eyes myelofibrosis drug Ojjaara’s reimb progress
• by Eo, Yun-Ho Nov 22, 2024 05:55am